BioXcel Therapeutics, Inc.
BTAI
$2.07
$0.168.61%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -126.45% | -131.20% | 72.92% | 51.21% | 72.96% |
| Total Depreciation and Amortization | -2.60% | -2.60% | -2.56% | -1.28% | -2.53% |
| Total Amortization of Deferred Charges | 315.09% | 309.38% | 713.95% | -27.69% | -71.88% |
| Total Other Non-Cash Items | 953.04% | 138.84% | -177.38% | -468.31% | -134.41% |
| Change in Net Operating Assets | -20.63% | 144.36% | -137.07% | 146.79% | -116.65% |
| Cash from Operations | -14.99% | 45.74% | 31.98% | 44.87% | 56.53% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 8,069.66% | -97.44% | -47.63% | 194.78% | -- |
| Repurchase of Common Stock | -- | 100.00% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -4,800.00% | 98.17% | -586.32% | 28.97% | -- |
| Cash from Financing | 8,166.96% | -97.42% | -50.42% | 101.41% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 218.01% | 30.40% | -87.01% | 57.43% | 57.74% |